Dr. Michael Tymianski, Head, Division of Neurosurgery, UHN and Senior Scientist, Toronto Western Research Institute, has developed a drug, NA-1, that could potentially revolutionize treatment for stroke patients. The drug will soon be tested in third phase clinical trials.(Photo: UHN)
The only stroke medication on the market has a laundry list of restrictions.
Krembil Neuroscience Centre's Dr. Mike Tymianski has been working on a new stroke drug, called NA-1, for 17 years.
He starts a major round of tests on humans in January that could be life-changing for thousands of stroke patients.
Read the Full Story in the Globe and Mail
Related Links
